weight loss information
|
Pills to Reduce Hunger Pangs & Lower Calorie IntakeWeight Loss Appetite SuppressantsThese medications suppress your appetite so you feel less hungry. They work by changing levels of brain chemicals (neurotransmitters) that regulate satiety (fullness) and appetite. In addition, some weight loss appetite suppressants slightly increase your metabolic rate - the rate at which your body burns calories. Examples of weight loss appetite suppressants include: Diethylpropion hydrochloride (eg. Tenuate)
Who Are Weight Loss Appetite Suppressants Designed For?Appetite suppressant medications are designed for the treatment of obesity patients (those with a Body Mass Index of 30+). They should be used in combination with a calorie-controlled weight-loss diet and physical exercise program. Do Weight Loss Appetite Suppressants Work?Weight loss results with appetite suppressants are not well documented in clinical trials. More research is needed. In one study, obese patients using phentermine for 9 months with a 1,000-calorie-a-day diet reduced weight by 26.9 lb (12.2 kg) compared to weight loss of 10.5 lb (4.8 kg) with the diet only. Studies on diethylpropion are ambivalent. Some indicate weight loss; others no weight loss. Weight Loss Appetite Suppressants Ineffective AloneIt's important to know that weight loss pills don't work without lifestyle changes. So weight loss appetite suppressants must be combined with diet and exercise. Lastly, weight lost is typically regained once you stop taking the appetite suppressants. Sources include: Arterburn D, Noel PH . Obesity. Clinical Evidence, 6: 463–470. Bonow RO, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Journal of the American College of Cardiology, 32(5): 1486–1588. Kahn MA, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. New England Journal of Medicine, 339(11): 713–718. Gardin JM, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA, 283(13): 1703–1709. Hershel J. Heart valve disorders and appetite-suppressant drugs. Editorial. JAMA, 283(13): 1738–1739. |
|
com